September 2018


In this Issue

Real-World SFA Decision-Making

Contextualizing the current landscape of data and devices.



Guest Chief Medical Editors’ Page

Real-World SFA Decision-Making

By Marianne Brodmann, MD, and William A. Gray, MD


Use Caution in Comparing SFA Trial Data

Not all superficial femoral artery device trials are created equal—in fact, none are.

By William A. Gray, MD; and Mario Landini

Roundtable Discussion: Surveying the Landscape: SFA Drug Delivery Trial Designs and Data

Experts discuss key elements of SFA trials, whether a global algorithmic approach to treating SFA disease is possible, and the limitations of cross-trial platform comparisons.

Moderator: William A. Gray, MD
Panel: Gary M. Ansel, MD; Koen Deloose, MD; Michael R. Jaff, DO; and Peter A. Schneider, MD

SPEED: A New Initiative in Real-World PAD Evidence Evaluation

An overview of the FDA’s new multistakeholder project to support real-world evidence evaluation for devices aimed at treating peripheral artery disease.

By Misti Malone, PhD

Separating Regulatory and Clinical Standards

Understanding the FDA device approval process and the difference between data from premarket and postapproval trials to make informed clinical decisions.

By Gary M. Ansel, MD; and Raghu Kolluri, MD, RVT, RPVI

Challenges Facing Current and Next-Generation SFA Technologies

A discussion of anatomic barriers to treatment, evolving trial designs, and the impact of reimbursement.

By Krishna Rocha-Singh, MD

Roundtable Discussion: SFA Vessel Prep in the Real World

A discussion on the current role of vessel preparation, when to use it and when not to use it, device selection, and data related to cost-effectiveness and algorithm creation.

Moderator: Marianne Brodmann, MD
Panel: Ehrin J. Armstrong, MD; Lawrence A. Garcia, MD; Gunnar Tepe, MD; Jos C. van den Berg, MD, PhD; and Thomas Zeller, MD

Options for In-Stent Restenosis in 2018

Capabilities and limitations of current technologies and available data.

By Brian G. DeRubertis, MD, FACS

Bioresorbable Stent Technology for Femoropopliteal Disease Treatment: Where Do We Stand?

Appraising the current literature on bioresorbable technology use in the SFA, what can be learned from the coronary experience, and the future of bioresorbable stents in this anatomy.

By Sabine Steiner, MD; Andrej Schmidt, MD; and Dierk Scheinert, MD

Transforming Open to Endo: Percutaneous Bypass as an Option for Long-Segment SFA Disease

A brief review of the Detour procedure technique, proposed advantages, and potential clinical applications.

By James D. Joye, DO, FACC, FSCAI


Sponsored by ROX Medical

Considering a New Approach to Treatment of Uncontrolled Hypertension With the ROX Coupler Device

A discussion with Dr. Krishna Rocha-Singh and Prof. Dr. Felix Mahfoud on what makes the ROX Coupler device different from other hypertension interventions, how to implant the device, clinical study results, and anticipated results from ongoing studies.

With Krishna Rocha-Singh, MD; and Felix Mahfoud, MD
Sponsored by Intact Vascular, Inc.

Post-PTA Dissection: Clinical Impact, Identification, and Repair

Discussion on the prevalence of post-angioplasty dissections, guidelines for their identification, and the use of the Tack Endovascular System® for repair.

With Ehrin J. Armstrong, MD, MSc; Nicolas W. Shammas, MD, MS, EJD; and Christian Wissgott, MD


Sponsored by Medtronic

Use of DCBs in Long Femoropopliteal Lesions: Where Do We Stand?

By Gary M. Ansel, MD



An Interview With Luis Mariano Palena, MD

Dr. Palena discusses the necessary skills for tackling challenging CLI cases, his ongoing research of new technology in this area, and his educational work around the world, particularly as Course Director of the CLIC meeting series.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.